Hopper raising at RAD. This time it looks a bit more positive.
Diagnostics specialist Lantheus, capitalised at $8 billion on the Nasdaq, likes the look of Aussie Radiopharm Theranostics.
Street Talk understands Lantheus has agreed to pay a 47 per cent premium to Radiopharm’s last close to come in as a cornerstone investor on an equity raise of up to $65 million. It will tip in $US7 million at 5¢ a share, with the option to top up by another $US5 million.
If he could secure a similar investment here with less dilution it would improve CHM's image a lot. An US Pharma giant investing, that's what the market needs as a reassurance.
GLTA
Ann: Notice of Extraordinary General Meeting/Proxy Form, page-243
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $7.017K | 1.754M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 3152363 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13492653 | 21 |
View Market Depth
| Last trade - 09.59am 24/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |